previously proposed that RIG‐I activation was critical for responsiveness to checkpoint blockade, their results—primarily derived from melanoma B16 cell lines—showed that RIG‐I activation enhanced the therapeutic effects of anti‐CTLA4 therapy [52]. The gene discussed is CTLA4; the disease is melanoma.